Cumulative effects of therapies on disability in relapsing multiple sclerosis.

Fabien RollotRomain CaseyEmmanuelle LerayMarc DebouverieGilles EdanSandrine WiertlewskiBertrand AudoinDavid-Axel Laplaud

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)

Long-term use of treatments in RRMS has a stronger beneficial cumulative impact than only early uses and delays the occurrence of moderate disability and conversion to SPMS.

Keyphrases

multiple sclerosis
white matter
risk assessment
high intensity